U-4140

REDUCING THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CV DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CKD AT RISK OF PROGRESSION AND WITHOUT TYPE II DIABETES AFTER AT LEAST 4 MONTHS OF TREATMENT